November 2017

Dravet syndrome is a serious form of childhood epilepsy that first shows up in babies at six to nine months old, resulting in cognitive impairments, autistic-like behaviors, and premature death.  About 15 percent of children with Dravet syndrome die before they reach the age of 13, according to William Catterall, a lead researcher, professor, and […]

by

Doral, FL, Nov. 28, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, commences pre-launch human trials on new CBD formula to fight against the U.S. opioid epidemic under […]

by

Whenever Jonathan Streetman posts new content, you’ll get an email delivered to your inbox with a link. Email notifications are only sent once a day, and only if there are new matching items. … read more at: https://www.heraldtimesonline.com/news/local/chronic-pain-hemp-oil-product-offers-ray-of-hope/article_1209c748-a483-59d8-8f15-d57455e9e7df.html

by

Doral, FL, Nov. 28, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, commences pre-launch human trials on new CBD formula to fight against the U.S. opioid epidemic under […]

by

Doral, FL, Nov. 28, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, commences pre-launch human trials on new CBD formula to fight against the U.S. opioid epidemic under […]

by

George E. Anastassov, MD, CEO of AXIM Biotech, told us the main rationale behind using chewing gum as the delivery system for Cannabidiol (CBD) is that “the oral-pharyngeal mucosa offers​ extensive territory for rapid and controlled absorption of the API and the avoidance of first pass metabolism​.” “Within 20 minutes, the oral mucosa absorbs 80 […]

by

Taking a selfie seems like a harmless act, but it caused serious negative health effects for one teenager. Doctors at Dalhousie University in Canada discovered a young girl, who previously suffered from a seizure, experienced seizure-like episodes moments after she took a selfie, according to a case study.  Read: Cannabidiol, A Compound In Marijuana, May Reduce […]

by

Posted in: Medical Research News | Medical Condition News | Pharmaceutical News Tags: Ache, Acute Pain, Antidepressant, Calcium, Calcium Channel Blocker, Cannabis, Cluster Headache, Headache, Migraine, Musculoskeletal, Neurology, Pain, Pharmaceutical, Prophylaxis, Stomach, Stomach Pain … read more at: https://www.news-medical.net/news/20170624/Cannabinoids-found-to-be-suitable-treatment-for-migraine-attacks.aspx

by

OAKPOINTE COMMUNITIES AND PRESIDIO RESIDENTIAL CAPITAL RECEIVE CITY APPROVAL TO DEVELOP LAKEPOINTE URBAN VILLAGE, A 214-ACRE MASTERPLANNED COMMUNITY   Mixed-Use Development in Southeastern King County to Include 850,000-Square-Foot Entertainment and Lifestyle Center, More Than 1,500 Homes, a 20-Acre Lake, Open Space and Trails   Oakpointe Communities and Presidio Residential Capital have received unanimous approval from the […]

by

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum. The […]

by

­­ NEW YORK, Nov. 22, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter ended September 30, 2017, and provided an overview of recent operational highlights. “We are very excited to see clinical evidence of our theory and the therapeutic […]

by